Splenic Hilar Nodes in Splenic Flexure Cancer

NCT ID: NCT04666883

Last Updated: 2020-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2021-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Report the incidence of metastases to the splenic hilar lymphnodes from splenic flexure primaries. This mode of spread has not been previously characterized for these tumours.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colon Cancer Metastases, Lymphatic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Splenic flexure cancer patients

Splenic flexure cancer patients

Review of records and follow up

Intervention Type OTHER

Follow up to identify patients who developed splenic hilar nodal metastases

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Review of records and follow up

Follow up to identify patients who developed splenic hilar nodal metastases

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All splenic flexure cancer patients

Exclusion Criteria

* No consent to data utilization
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Rome Tor Vergata

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Giuseppe Sigismondo Sica

Associate Professor, Head of Department

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Policlinico Tor Vergata

Roma, RM, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bruno Sensi, MD

Role: CONTACT

Phone: 3385352902

Email: [email protected]

Giuseppe S Sica, MD, PhD

Role: CONTACT

Phone: 3385333659

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Bruno Sensi, MD

Role: primary

Giuseppe S Sica, MD, PhD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

REGISTROSPERIMENTAZIONI/21

Identifier Type: -

Identifier Source: org_study_id